Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 4, 2018Journal of Clinical OncologyOpen Access

Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SHScott F. HuntingtonYale Cancer CenterGKGottfried von KeudellBeth Israel Deaconess Medical CenterADAmy J. DavidoffNational Cancer Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Huntington et al. (2018) studied this question.

synapsesocial.com/papers/6a72568a35aa2c282ce3350chttps://doi.org/10.1200/jco.18.00122
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)2012 · 309 citations
  2. 2How I treat relapsed and refractory Hodgkin lymphoma2011 · 144 citations
  3. 3Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi2015 · 109 citations
  4. 4Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology2017 · 142 citations
  5. 5Indication-specific pricing of pharmaceuticals in the US healthcare system2017 · 43 citations